Endo settles Oklahoma opioid case for $8.8M

Endo Pharmaceuticals agreed to pay $8.8 million to Oklahoma to settle claims its marketing played a role in fueling the opioid crisis, The Wall Street Journal reported. 

Oklahoma Attorney General Mike Hunter's office told the Journal that most of the settlement money will go into an opioid lawsuit settlement fund, which includes the $85 million Teva agreed to pay the state last May.   

In addition to the $8.8 million, Endo agreed that it wouldn't employ or contract sales representatives, speakers or opinion leaders to promote opioids in Oklahoma or hold speaking events in the state. It also said it wouldn't financially support any promotional materials about opioids, including brochures, newsletters or books.  

The drugmaker also terminated all research and development of opioid medications. 

The settlement with Oklahoma fully resolves the state's investigation into Endo and its affiliates, the Journal reported. 

Mr. Hunter commended the drugmaker, saying, "When they saw a problem, corporate executives proactively worked, internally and with stakeholders, to find a solution, not a cover-up, as we have discovered with numerous other companies during our yearslong investigation."

Endo did not admit wrongdoing, fault or liability in the settlement with Oklahoma. In September, the drugmaker also agreed to pay $11 million to two Ohio counties to settle lawsuits related to its opioid drugs. 

Read the full article here

More articles on pharmacy:
GAO report hits lax oversight of 340B drug program
Venture capitalist launches company to bring drug prices down
AMAG Pharmaceuticals replacing CEO, cutting 2 drugs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers